Cited by 481HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentCervical Cancer and HPV Research

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.

Open access

Nel, Annalene, van Niekerk, Neliëtte, Kapiga, Saidi, Bekker, Linda-Gail, Gama, Cynthia, Gill, Katherine, Kamali, Anatoli, Kotze, Philip, Louw, Cheryl, Mabude, Zonke, Miti, Nokuthula, Kusemererwa, Sylvia, Tempelman, Hugo, Carstens, Hannelie, Devlin, Brid, Isaacs, Michelle, Malherbe, Mariëtte, Mans, Winel, Nuttall, Jeremy, Russell, Marisa, Ntshele, Smangaliso, Smit, Marlie, Solai, Leonard, Spence, Patrick, Steytler, John, Windle, Kathleen, Borremans, Maarten, Resseler, Sophie, Van Roey, Jens, Parys, Wim, Vangeneugden, Tony, Van Baelen, Ben, Rosenberg, Zeda·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1602046

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda. METHODS: In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings containing either 25 mg of dapivirine or placebo. Participants inserted the rings themselves every 4 weeks for up to 24 months. The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion. RESULTS: A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years). The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P=0.04). There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P=0.43 for treatment-by-age interaction). Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group. Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]). However, no clear pattern was identified. CONCLUSIONS: Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo. (Funded by the International Partnership for Microbicides; ClinicalTrials.gov number, NCT01539226 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1602046

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Self-citation
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Self-citation
Women’s Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa
van der Straten, A., Stadler, J., Montgomery, E., Hartmann, M., Magazi, B., Mathebula, F., Schwartz, K. D., Laborde, N. D., & Soto-Torres, L. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089118 · Cited by 259
Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
Amico, K. R., & Stirratt, M. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu266 · Cited by 117
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
Nel, A. M., Bekker, L., Bukusi, E. A., Hellström, E., Kotze, P. L., Louw, C. E., Martinson, F. E. A., Masenga, G. G., Montgomery, E., Ndaba, N. D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147743 · Cited by 113
Self-citation

Flagged first, then by citations

Show all 16 references

Research works printed but not linked: 1

Wensing AM, 2015, Top Antivir Med, 23, 132

Sorted by citations

Items 401–481 of 481

Pharmacists and the next generation of HIV pre-exposure prophylaxis
Griffith, K., & Romanelli, F. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.07.001 · Cited by 1
Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials—The Ring Study and DREAM
Steytler, J., van der Ryst, E., Craig, C., Baelen, B. V., Nuttall, J. P., van Niekerk, N., Mellors, J. W., Parikh, U. M., Wallis, C. L., & for the IPM 007 Study Team (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac804 · Cited by 1
Self-citation
Brief Report: HIV Drug Resistance Assessment Among Women Who Seroconverted During the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial
Parikh, U. M., Penrose, K. J., Heaps, A., Sethi, R., Goetz, B. J., Szydlo, D. W., Chandran, U. R., Palanee‐Phillips, T., Mgodi, N. M., Baeten, J. M., et al. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003308 · Cited by 1
An Update On long-acting Agents in HIV Therapy
Pezzati, L., Canavesi, G., & Rusconi, S. (2023) · Future Virology · doi:10.2217/fvl-2023-0097 · Cited by 1
Examination of Incidence of Sexually Transmitted Infections in the Ending the HIV Epidemic Priority Counties of the United States, 2005–2019
Bunting, S. R., Hunt, B. R., Johnson, A. K., Hazra, A., Nunez-Garcia, A., & Glick, N. R. (2023) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001910 · Cited by 1
The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development
Chapman, K., Rueda, S. T., Metzler, M., Holt, B. Y., Kahn-Woods, E., Thornton, D., & Gomez, G. B. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2024.1272950 · Cited by 1
Perception of couples’ on multipurpose prevention technology attribute choice: the case of MTN 045
Dandadzi, A., Young, A. M., Musara, P., Shapley‐Quinn, M. K., Kemigisha, D., Mutero, P., Mgodi, N. M., Etima, J., & Minnis, A. M. (2024) · BMC Public Health · doi:10.1186/s12889-024-19390-0 · Cited by 1
An Open Letter on Advancing HIV prevention: Augmenting an ecosystem-based approach to understand prevention decision-making
Gantayat, N., Baer, J., Gangaramany, A., & Pierce-Messick, R. (2025) · Gates Open Research · doi:10.12688/gatesopenres.16067.2 · Cited by 1
High Preference for Injectable Pre-exposure Prophylaxis among Young Women in Kenya
Zewdie, K., Kinuthia, J., Matemo, D. N., Wandera, C., Kemunto, V., Cherotich, I., Oyambra, T., Bi, M., Achieng, E., Odhiambo, S., et al. (2025) · AIDS and Behavior · doi:10.1007/s10461-025-04687-x · Cited by 1
HIV/AIDS infection: The beginning of the end for today's greatest pandemic?
Gutiérrez, F. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.04.004 · Cited by 1
Public health’s social contract: An obstacle in the advancement of effective HIV technologies
Bulled, N. L. (2019) · Global Public Health · doi:10.1080/17441692.2019.1585468 · Cited by 1
The Contraceptive Vaginal Ring
Mandelbaum, R. S., & Shoupe, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-46391-5_5 · Cited by 2
Long-acting injections for HIV prevention among women in sub-Saharan Africa
Krogstad, E. A., & Parker, I. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00613-4 · Cited by 1
Toward an intravaginal device to detect risk of preterm labor: a user-centered design approach in Sub-Saharan Africa
Smith, E., Milford, C., Ngure, K., Newmann, S. J., Thuo, N. B., Berrios, S., Beksinska, M. E., Mugo, N., & Rand, L. (2022) · Reproductive Health · doi:10.1186/s12978-022-01478-8 · Cited by 1
Dapivirine ring reduces HIV acquisition
Fenner, A. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.263
Vaginalring mot hivsmitte
Brodwall, K. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.16.1081
Women’s estimated HIV infections from sex in trials of pre-exposure prophylaxis in Africa: Implications for HIV prevention strategiesPreprint
Gisselquist, D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/146530
Optimism and concern at IAS 2017
Mayer, K. H. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30158-3
The role of drugs in HIV prevention
Kembaren, T. (2018) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/125/1/012088
Interference with HIV infection of the first cell is essential for viral clearance in a pre-exposure prophylaxis modelPreprint
Moyano, A., Lustig, G., Rodel, H. E., Tibor Antal, A., & Sigal, A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/435552
A combination of Interferon Stimulated Genes is more effective than IFNα and IFNβ in reducing HIV-1 replication in human cervicovaginal tissuesPreprint
Rollenhagen, C., Gui, J., Doncel, G. F., & Asin, S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/610964
Educating men about vaginal microbicides: considerations from Kenya
Gitome, S. W., Kwena, Z., Harper, C. C., Cohen, C. R., & Bukusi, E. A. (2019) · Culture Health & Sexuality · doi:10.1080/13691058.2019.1627583
Evaluation of Topical Dispenser Systems for Vaginal Delivery of Feminine Medications
Toerien-Hayes, C. (2019) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20190704.13
An HIV-free generation: review of prevention strategies
Moodley, I. (2019) · South African Family Practice · doi:10.4102/safp.v61i6.5067
Antiretroviral drugs differentially modulate glucocorticoid activity via the glucocorticoid receptor in vitro
Kuipa, M. (2019) · Open University of Cape Town (University of Cape Town)
Electrospun fibers and nanoparticles for the prevention of sexually transmitted infections.
Tyo, K. M. (2019) · doi:10.18297/etd/3344
Performance of Male Condoms When Used With and Without a Silicone Placebo Vaginal Ring—A Randomized, Crossover Trial
Nel, A. M., Malherbe, M., van Niekerk, N., Beksinska, M. E., Greener, R., Smit, J. A., Frezieres, R. G., & Walsh, T. L. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002397
Self-citation
Prevention of HIV Infection
Fong, I. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-36966-8_1
Uso de anillo vaginal con dapivirina para prevención de infección por HIV en mujeres
Benso, J. D., & Ciapponi, A. (2020) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v22i4.4261
Preventing HIV With Pre-exposure Prophylaxis: Current and Emerging Modalities
Broholm, C., Yingling, C. T., & Vail, R. M. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.07.021
Vaginal hormonal releasing system: a method of contraception and prevention of reproductive tract microbiocenosis disorders
Dobrokhotova, Y. E., Bondarenko, K. R., & Андреевна, Ш. П. (2021) · Russian Journal of Human Reproduction · doi:10.17116/repro20212704184
The use of nanoparticles and electrospun fibers for intravaginal delivery to treat viral and bacterial infections and electrophysiological measurements of synthetic chloride channels.
Minooei, F. (2020) · doi:10.18297/etd/3559
Prevention Clinical Trials: Highlights of Evidence and Research
Baxter, C., & Karim, Q. A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7101-5_256
Prevention Clinical Trials: Highlights of Evidence and Research
Baxter, C., & Karim, Q. A. (2017) · Springer eBooks · doi:10.1007/978-1-4614-9610-6_256-1
Evaluation of Topical Dispenser Systems for Vaginal Delivery of Feminine Medications
Toerien-Hayes, C., Nguyen, Q., Woods, J., Liu, Q., Kupiec, T. C., & Vu, N. T. (2020) · Advanced Biomedicine · doi:10.54730/abm.2020.020603
Counterfactual groups to assess treatment efficacy in HIV prevention trials in high risk populations in UgandaPreprint
Abaasa, A. M., Mayanja, Y., Anywaine, Z., Kusemererwa, S., Ruzagira, E., & Kaleebu, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1811079/v2
Self-citation
Dapivirine Vaginal Ring for HIV Prevention in Women in South Africa
Gill, K., & Bekker, L. (2022) · touchREVIEWS in Infectious Diseases · doi:10.17925/id.2022.1.1.26
Self-citation
Exposure to prevention information, sexual health, and experience of discrimination: HIV exploration among high-risk populations in Vietnam
Huyen, T. N. T., Pumtong, S., Sangroongruangsri, S., & Anuratpanich, L. (2023) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres23.1643_11.4.557
Women’s motivations for participating in the dapivirine vaginal ring open label extension study
Naidoo, K., Montgomery, E., Katz, A. W. K., Garcia, M., Naidoo, S., & Mansoor, L. E. (2023) · AIDS Care · doi:10.1080/09540121.2023.2260145
Narratives from women using the dapivirine vaginal ring in an open label extension study by Kalendri Naidoo.
Naidoo, K. (2022) · doi:10.29086/10413/22674
Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment
Hart, T. A., Tan, D. H. S., Rana, J., Tengra, Z., Wilton, J., & Bayoumi, A. M. (2024) · doi:10.32920/25360306.v1
Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment
Hart, T. A., Tan, D. H. S., Rana, J., Tengra, Z., Wilton, J., & Bayoumi, A. M. (2024) · doi:10.32920/25360306
An Open Letter on Advancing HIV prevention: Augmenting an ecosystem-based approach to understand prevention decision-making
Gantayat, N., Baer, J., Gangaramany, A., & Pierce-Messick, R. (2024) · Gates Open Research · doi:10.12688/gatesopenres.16067.1
Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037)
Ho, K. S., Hoesley, C. J., Anderson, P. L., Fernández-Romero, J. A., Friedland, B., Kelly, C. W., Jiao, Y., Edick, S., Brand, R. M., Ayudhya, R. P. K. N., et al. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003506
Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention
Peebles, K., Matrajt, L., Baeten, J. M., Palanee‐Phillips, T., Brown, E. R., & for the MTN-020/ASPIRE Study Team (2024) · International Journal of STD & AIDS · doi:10.1177/09564624241300199
Preferences for Long-Acting Pre-Exposure Prophylaxis for HIV Prevention Among Pregnant Women Without HIV in Kisumu and Siaya, Kenya: Results from a Discrete Choice ExperimentPreprint
Concepcion, T. L., Kinuthia, J., Abuna, F., Akim, E., Flaherty, B. P., Gómez, L., John-Stewart, G. C., Mukenyi, E., Ngumbau, N. M., Mogaka, J. N., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5068622
Statistical methods in the analysis of multicentre HIV randomized controlled trials in the African region: a scoping review
Mazinu, M., Gwebushe, N., Manda, S., & Reddy, T. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02441-w
Risk Compensation in the Context of Sexually Transmitted Infections in Women Using the Dapivirine Vaginal Ring in Africa: A Scoping Review
Dine, R. D., Ogunniyi, T. J., Yisa, S. S., Rutaganira, E., Sindayigaya, P., Batisani, K., Ojo, J. O., Wazhi, G. B., Oke, A. E., Ibrahim, A. D., et al. (2025) · International Journal of Sexual Health · doi:10.1080/19317611.2025.2514031
HIV Prevention
Baumgartner, K., Bositis, C. M., Hanft, W., & Chu, C. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0014
Counterfactual Groups to Assess Vaccine or Treatment Efficacy in HIV Prevention Trials in High-Risk Populations in Uganda
Abaasa, A. M., Mayanja, Y., Anywaine, Z., Kusemererwa, S., Ruzagira, E., & Kaleebu, P. (2025) · Vaccines · doi:10.3390/vaccines13080844
Self-citation
Human Immunodeficiency Virus Types 1 and 2: Virology, Host Response, Treatment, and Prevention
Tang, J. ‘., Goepfert, P., & Kaslow, R. A. (2025) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_66-1
Current standards for HIV vertical transmission prevention
Lishman, J., Navér, L., & Rabie, H. (2025) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2025.101663
Bacterial and Viral Sexually Transmitted Infections
Hammo, A. H., Thamer, R. A., Alhafidh, N. M., Abdulrahman, T. S., & Saadi, A. M. (2025) · Pharaonic Journal of Science · doi:10.71428/pjs.2025.0211
HIV prevention for young African women is about choice
Stewart, J. C., Heffron, R. A., & Celum, C. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00269-3
Pre-Exposure Prophylaxis (PrEP)-Associated HIV Monitoring and Self-Testing
Zhu, Y., & Sell, J. K. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf155 · Cited by 1
Additional file 2 of Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa
Leslie, J., Kiweewa, F. M., Palanee‐Phillips, T., Bunge, K. E., Mhlanga, F., Kamira, B., Baeten, J. M., Katz, A. W. K., Hillier, S., & Montgomery, E. (2021) · Figshare · doi:10.6084/m9.figshare.14478522
Additional file 1 of Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa
Leslie, J., Kiweewa, F. M., Palanee‐Phillips, T., Bunge, K. E., Mhlanga, F., Kamira, B., Baeten, J. M., Katz, A. W. K., Hillier, S., & Montgomery, E. (2021) · Figshare · doi:10.6084/m9.figshare.14478519
Introducing personalized patient care in overactive bladder management using the MedRing OAB system for intravaginal oxybutynin administration
Peltenburg, S. I., Koopmans, I., Heerema-Snoep, O., Klaassen, E. S., Juachon, M. J., Otten, A., & Klarenbeek, N. B. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2617683
Comparative Effectiveness of Daily Oral and Long-acting Injectable Prep: A Critical Review of Clinical Evidence and Public Health Implications
Croner, A. F. T., Leite, D. I., Brum, I. S., Dias, M. D. C. A., Pimentel, L. C. F., Bastos, M. M., & Boechat, N. (2026) · Current HIV Research · doi:10.2174/011570162x426548251031113228
Attribute development for a discrete choice experiment to examine preferences for long-acting HIV prevention products among pregnant and breastfeeding women
Ngugi, S. W., Echoka, E., Were, V. O., Thuo, N. B., Ogello, V., Gikwa, M., Muteti, N., Mwangi, P. M., Kazungu, J., & Ngure, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-45900-8
Caractérisation du profil d’anticorps et de leurs activités inhibitrices chez des patients contrôleurs du VIH
Klingler, J. (2019) · theses.fr (ABES) · doi:10.70675/8ab46952z7743z4999zb432zf1bf23dd682f
Etude des réponses T CD4+ et CD8+ induites chez l’homme par différentes stratégies vaccinales anti-VIH-1 utilisant des lipopeptides
Surénaud, M. (2019) · theses.fr (ABES) · doi:10.70675/614b41efzcc3cz45c3z9c65z9c0c996bef95
La prophylaxie pré-exposition de l’infection par le virus de l’immunodéficience humaine : une révolution en prévention
Molina, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.12.032
Estimated adherence to the Dapivirine Vaginal Ring and its associated factors among African women: A systematic review and meta-analysis
Dine, R. D., Muraca, G. M., Sadeghirad, B., Couban, R., Nyambi, A., Silva, J., & Mbuagbaw, L. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006422
High Interest in the PrEP (Dapivirine) Ring Among U.S. Low-Income Latina Women: Results From a Community Clinic
Gollub, E. L., Finver, E., Pizzella, L., Raposo, C., Hernandez, J., Ruggiero, A., & Martins-Mandel, K. (2026) · AIDS Education and Prevention · doi:10.1521/aeap.2026.38.3.189
Preparedness of Primary Health Care Clinic (PHCC) Providers for the Provision of Oral Pre-exposure Prophylaxis (PrEP) to Adolescent Girls and Young Women (AGYW): Experiences from KwaZulu-Natal, South Africa
Mahlase, G., Govender, E., Mohan, J., & Karim, Q. A. (2026) · AIDS and Behavior · doi:10.1007/s10461-026-05173-8
Vaginal Microbiota and Cytokines Among Pregnant and Breastfeeding Women in Clinical Trials of the Dapivirine Vaginal Ring and Oral Tenofovir Disoproxil Fumarate/Emtricitabine
Petrina, M. A. B., Dong, T. Q., Beamer, M. A., Bunge, K. E., Fairlie, L., Mhlanga, F., Balkus, J. E., Noguchi, L., Piper, J., Brown, E. R., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag329
Subdermal implants for HIV prevention with increased dapivirine release rates
Wang, S., Murtadha, R. Z., & Malcolm, K. R. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127118
Use of a hydrophilic excipient to modulate the release of dapivirine, copper ions and zinc ions from a matrix-type vaginal ring
Shen, X., Zhao, X., Boyd, P., Bashi, Y. H. D., McCoy, C. F., Murtadha, R. Z., & Malcolm, K. R. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127143
Pre-Exposure Prophylaxis for the Biomedical Prevention of HIV Infection
Allan‐Blitz, L., & Mayer, K. H. (2026) · Oxford University Press eBooks · doi:10.1093/9780191873881.003.0006
‘Community perspectives on long-acting injectable PrEP among Haitians and Haitian Americans living in Florida: a qualitative study’
Sternberg, C. A., Berthold, C., Beauvoir, M., Titus, M., Horne, C. V., Philbin, M. M., Dale, S. K., & Alcaide, M. L. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2687966
A rapid qualitative analysis of health care worker and community focus groups on determinants and implementation strategies for long-acting PrEP in antenatal and postpartum settings in Kenya
Concepcion, T., Strong, M., Kinuthia, J., Otieno, F. O., Akim, E., Aketch, H., Gomez, L., John-Stewart, G. C., Moki-Suh, B., Ngumbau, N. M., et al. (2026) · Discover Health Systems · doi:10.1007/s44250-026-00415-x
Pre-exposure prophylaxis for women: enhancing HIV prevention in primary care
Hitchings, E., & Rowlandson, K. (2026) · Primary Health Care · doi:10.7748/phc.2026.e1897
State of the art in intravaginal rings: from material engineering to 3D-printed multipurpose delivery systems
Trallero, J. M., Anaya, B. J., Serrano, D. R., & Notario-Pérez, F. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115304
Estimated benefits of providing on-demand pre-exposure prophylaxis options for cisgender women in South Africa: A modeling study
Stansfield, S. E., Moore, M., Boily, M., Hughes, J. P., Donnell, D. J., Bekker, L., & Dimitrov, D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0357094
Self-citation
Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis
Feng, X., Wu, X., Fitzpatrick, T., Ong, J. J., Bavinton, B. R., Cheng, C., Chen, Y. Q., Phanuphak, N., Jiang, H., Huang, X., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104189
Ethanolic and water extracts of the medicinal plant Houttuynia cordata inhibit HIV-1 infection in vitro
Satthakarn, S., Chuenchitra, T., Hladik, F., Levy, C., Tewtrakul, S., Saipin, K., Promsong, A., Bunluepuech, K., & Nittayananta, W. (2026) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-026-00920-7
Pre-exposure Prophylaxis Outcomes from a Multilevel Cluster-Randomized Trial Among Adolescent Girls and Young Women in Tshwane, South Africa
Bonner, C. P., Minnis, A. M., Browne, F. A., Speizer, I. S., Nyblade, L. C., Ndirangu, J., Kline, T., Smith, A., Ahmed, K., & Wechsberg, W. M. (2026) · AIDS and Behavior · doi:10.1007/s10461-026-05262-8
An intravaginal ring for HIV pre-exposure prophylaxis: assessment of safety and pharmacokinetics in a randomized, placebo-controlled clinical trial
Vincent, K. L., Moss, J. A., Marzinke, M. A., Pyles, R. B., Dawson, L., Olive, T. J., Butkyavichene, I., Castonguay, A. E., Cortez, J. M., Remedios-Chan, M., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1955105
BindingDB Entry 50016869: Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2sn0f0p
BindingDB Entry 50008972: The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
BindingDB (2021) · UC San Diego · doi:10.7270/q2f76h0j

Authors: Nel, A., van Niekerk, N., Kapiga, S., Bekker, L.-G., Gama, C., Gill, K., Kamali, A., Kotze, P., Louw, C., Mabude, Z., Miti, N., Kusemererwa, S., Tempelman, H., Carstens, H., Devlin, B., Isaacs, M., Malherbe, M., Mans, W., Nuttall, J., Russell, M., Ntshele, S., Smit, M., Solai, L., Spence, P., Steytler, J., Windle, K., Borremans, M., Resseler, S., Van Roey, J., Parys, W., Vangeneugden, T., Van Baelen, B., & Rosenberg, Z.
Affiliations: International Partnership for Microbicides (US)
ORCID: Kapiga, Saidi
Bekker, Linda-Gail
Gill, Katherine
Kotze, Philip
Kusemererwa, Sylvia
Isaacs, Michelle
Nuttall, Jeremy
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-12
Volume: 375
Issue: 22
Pages: 2133-2143
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1602046
OpenAlex: W2558446330
Cited by: 479
References: 16
Citations by year: 2026: 31 · 2025: 39 · 2024: 34 · 2023: 43 · 2022: 50 · 2021: 72 · 2020: 40 · 2019: 78 · 2018: 57 · 2017: 32 · 2016: 3
FWCI: 52.34
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Keywords: dapivirine, vaginal ring, HIV prevention, HIV-1 seroconversion, women, drug safety
MeSH terms: Adolescent, Adult, Double-Blind Method, Female, HIV Seropositivity, Humans, Middle Aged, Pregnancy, Pyrimidines, RNA, Viral, South Africa, Uganda, Vagina, HIV-1, HIV Infections, Incidence, Reverse Transcriptase Inhibitors, Drug Resistance, Viral, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks